AstraZeneca
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, AstraZeneca sits in the top decile of US sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count).
AstraZeneca: 1,285 sponsored US clinical trials, 160 recruiting.
AstraZeneca sponsors 1,285 registered US clinical trials on ClinicalTrials.gov, 160 of them currently recruiting, and 883 completed. 484 of these trials are in Phase 3-4 (later-stage) and 720 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 24 trials.
Top-decile sponsor footprint
AstraZeneca ranks in the top decile of sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
883 of 987 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,285 total, page 26 of 26
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00061022
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
NCT00163527
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
NCT00108004
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
NCT00239681
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
NCT00240318
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
NCT00107107
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
NCT00111540
Extension Study for 2993-112
NCT01789957
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
NCT00060489
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
NCT00225589
Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide
NCT00044707
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
NCT00044694
307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects
NCT00255502
Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects
NCT00255528
Evaluation of the Bioavailability of Pramlintide
NCT00042471
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
NCT00035984
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
NCT00042458
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
NCT00280865
CAFE Comparison of Atypicals in First Episode of Psychosis
NCT00034892
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
NCT00039013
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
NCT00039026
Reversal of Ventricular Remodeling With Toprol-XL
NCT00038077
A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00034905
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
NCT00241553
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00014690
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
NCT00241514
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
NCT00241540
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
NCT00241527
Iressa Expanded Access Program (EAP)
NCT00034879
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
NCT00232661
Long Term Open Follow-up With H376/95 vs. Warfarin
NCT00206063
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
NCT00241449
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
NCT00227318
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
NCT00657904
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
NCT00846976
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 444 |
| Phase 2 | 276 |
| Phase 3 | 437 |
| Phase 4 | 47 |
Therapeutic Areas
What is open in the AstraZeneca pipeline
160 recruiting of 1,285 indexed (12% open); 883 completed (69%).
Phase mix: 484 late (III/IV) vs 720 early (I/II) (balanced across stages).
Top condition: Non-Small Cell Lung Cancer (24 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AstraZeneca: open-pipeline peers nationwide
Peers matched on 1,285 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
AstraZeneca sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,285 trials (± recruiting share)
- University of Colorado, Denver · 1,283 trials · 21% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
Related
What to do with this AstraZeneca page
1,285 registered trials is a research-attention snapshot, not an endorsement of AstraZeneca or any single study.
- 160 of AstraZeneca's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition AstraZeneca studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AstraZeneca pipeline card: 1,285 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.